Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis

详细信息    查看全文

• 作者：Ying Liu^a ; ^{ying.liu@biogen.com} ; Timothy Vollmer^b ; ^{timothy.vollmer@ucdenver.edu} ; Eva Havrdova^c ; ^{Eva.Havrdova@lf1.cuni.cz} ; Katherine Riester^a ; ^{katherine.riester@biogen.com} ; Andrew Lee^a ; ^{andrew.lee@biogen.com} ; Glenn Phillips^a ; ^{glenn.phillips@biogen.com} ; Ping Wang^a ; ^{ping.wang@biogen.com} ; Guido Sabatella^a ; ^{guido.sabatella@biogen.com}
• 关键词：ARR ; annualized relapse rate ; BDI-II ; Beck Depression Inventory-II ; EQ-5D ; Euro-Qol 5-Dimensions ; IFN ; interferon ; IM ; intramuscular ; MRI ; magnetic resonance imaging ; MS ; multiple sclerosis ; MSIS-29 ; 29-item Multiple Sclerosis Impact Scale ; OR ; odds ratio ; PHYS ; physical impact subscale ; PRO ; patient-reported outcome ; PSYCH ; psychological impact subscale ; QoL ; quality of life ; RRMS ; relapsing-remitting multiple sclerosis ; SC ; subcutaneous ; VAS ; visual analog scale
• 刊名：Multiple Sclerosis and Related Disorders
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：11
• 期：Complete
• 页码：18-24
• 全文大小：616 K
• 卷排序：11

文摘

Daclizumab demonstrated superior efficacy vs IM interferon beta-1a in DECIDE. DECIDE included PROs to assess impact of treatment from the patient's perspective. MSIS-29 score improvement was significantly greater for daclizumab at week 96. EQ-5D score improvement was significantly greater for daclizumab at week 96. Improvement in PROs with daclizumab was consistent with clinical/MRI outcomes.